This study was designed to characterize the endothelium-dependent contracting factor (EDCF) released by arachidonic acid (AA) and methacholine (MeCH) in the rabbit pulmonary artery. AA and MeCH contract the rabbit pulmonary artery; however, the effects of both are blocked by denuding the vessels and by administration of indomethacin (a cyclooxygenase inhibitor), dazoxiben (a thromboxane [TX] Acetylcholine also caused endothelium-dependent contractions in the rabbit pulmonary artery,4 the canine basilar artery,2 and the aorta from spontaneously hypertensive rats.5 Acetylcholine-induced contractions of spontaneously hypertensive rat aortas were blocked by indomethacin and the TXA2/prostaglandin (PG) H2 receptor antagonist SQ29548, whereas the TX synthase inhibitor dazoxiben failed to block contraction. As a result, it was suggested that PGH2 might be the endothelium-dependent contracting factor (EDCF) in aortic tissue of the spontaneously hypertensive rat. Other studies have shown that dazoxiben inhibits the endothelium-dependent contractions to MeCH in rabbit pulmonary artery,4 suggesting that the EDCF may be TXA2. The possibility exists that different EDCFs may mediate the response in the spontaneously hypertensive rat aorta and rabbit pulmonary artery. Taken collectively, these studies suggest that both AA and MeCH release an EDCF that is a cyclooxygenase metabolite and acts via the TXA2/PGH2 receptor. Although there are pharmacological insights into the nature of EDCF, there is
Q ) vascular endothelium in the regulation of vascular tone has been clearly demonstrated. The discovery of endothelial vasodilators, such as prostacyclin and endothelium-derived relaxing factor, as well as endothelial vasoconstrictors, such as endothelin, has greatly enhanced our understanding of the role of the endothelium in modulating vascular tone. Both arachidonic acid (AA) and methacholine (MeCH) act in an endothelium-dependent manner to affect responses in vascular smooth muscle. Early studies showed that AA caused endothelium-dependent contractions in canine femoral and pulmonary veins,1 canine basilar arteries,2 and rabbit aortas.3 These contractions were blocked by the cyclooxygenase inhibitor * prostacyclin * endothelial cells * cyclooxygenase indomethacin, but there were conflicting reports on their ability to be blocked by inhibitors of thromboxane (TX) synthase or lipoxygenase.1"2 Acetylcholine also caused endothelium-dependent contractions in the rabbit pulmonary artery,4 the canine basilar artery,2 and the aorta from spontaneously hypertensive rats.5 Acetylcholine-induced contractions of spontaneously hypertensive rat aortas were blocked by indomethacin and the TXA2/prostaglandin (PG) H2 receptor antagonist SQ29548, whereas the TX synthase inhibitor dazoxiben failed to block contraction. As a result, it was suggested that PGH2 might be the endothelium-dependent contracting factor (EDCF) in aortic tissue of the spontaneously hypertensive rat. Other studies have shown that dazoxiben inhibits the endothelium-dependent contractions to MeCH in rabbit pulmonary artery, 4 suggesting that the EDCF may be TXA2. The possibility exists that different EDCFs may mediate the response in the spontaneously hypertensive rat aorta and rabbit pulmonary artery. Taken collectively, these studies suggest that both AA and MeCH release an EDCF that is a cyclooxygenase metabolite and acts via the TXA2/PGH2 receptor. Although there are pharmacological insights into the nature of EDCF, there is conflicting chemical information on its structure. As a result, the identity of EDCF is still controversial.
The purpose of the present study was to more completely characterize the EDCF released by AA and MeCH in the rabbit pulmonary artery. Using a variety of chemical and pharmacological means, we determined the properties of the EDCF released by MeCH and AA.
Materials and Methods

VAascular Reactivity
Three-month-old male New Zealand White rabbits were anesthetized with intravenous sodium pentobarbital (120 mg/kg). The heart and lungs were removed as a unit and placed immediately in Krebs' bicarbonate buffer of the following composition (mM): NaCI 118, KCI 4 , CaCl2 3.3, NaHCO3 24, KH2P04 1.4, MgS04 1.2, and glucose 11, pH 7.4. The main pulmonary artery was identified at its origin from the right ventricle, and both left and right pulmonary arteries were dissected to their most distal end. The pulmonary artery distal to the first branching of the left or right pulmonary artery was used, and this is referred to as the intrapulmonary artery. After dissection, the tissue was cleaned of adherent lung parenchyma and connective tissue; care was taken not to disturb the endothelial layer. Rings of intrapulmonary artery (2-3 mm) were obtained and suspended in 15- After extraction into methylene chloride, the samples were dissolved in 100 ,ul acetonitrile, 5 ,ul diisopropylethylamine, 5 £1. N,N-dimethylformamide, and 3 ,l pentafluorobenzyl bromide and allowed to react for 40 minutes at 40°C. The compounds were extracted with hexane and converted to the trimethylsilyl ethers by incubating for 60 minutes at 60°C with bis(trimethylsilyl)trifluoroacetamide. GC/MS analysis was performed with a Finnigan SSQ-700 quadrupole mass spectrometer. The samples were analyzed by negative ion chemical ionization mass spectroscopy using a 14-m capillary DB-5 column with a linear gradient of 100-290°C over 10 minutes. The reagent gas was methane.
Radioimmunoassay of TXB2 and 6-Keto-PGFia Strips of rabbit intrapulmonary artery (3 mg wet weight) were incubated in HEPES buffer containing increasing concentrations of AA or MeCH for 15 minutes. In some experiments, inhibitors of AA metabolism were added to the buffer for 10 minutes before the addition of AA or MeCH. The synthesis of TXB2 and 6-keto-PGF,a was measured by specific radioimmunoassay (RIA) using the method of Campbell and Ojeda.9 The antibodies for TXB2 and 6-keto-PGF,a were produced in rabbits in our TXB2 and 5 pg/0.3 ml for 6-keto-PGFla. The crossreactivity of the antisera with known AA metabolites is less than 0.1%.
Cell Culture/Immunohistochemistry
Endothelial cells were isolated and cultured from rabbit pulmonary arteries by a modification of methods previously described.10 The arteries were dissected to their most distal ends within the lung, and all branch vessels were ligated at their origin from the main left or right pulmonary artery. The arteries were then removed and placed in RPMI 1640 media containing L-glutamine and HEPES (25 mM) and antibiotics (penicillin G, streptomycin, amphotericin, nystatin, and gentamicin) for approximately 15 minutes. The rinsed arteries were then cleaned of connective tissue and placed on damp sterile gauze in Petri dishes in a laminar flow hood. Collagenase (0.1%) in RPMI media was introduced into the vessel lumen with a polyethylene-tipped syringe, and both ends of the vessel were ligated with nylon sutures. The arteries were incubated at 37°C in an atmosphere of 5% CO2 in air for a minimum of 30 minutes, the lumen was then flushed twice with RPMI culture medium containing antibiotics, and the detached cells were collected into centrifuge tubes. The cells were sedimented by centrifugation at 200g for 10 minutes, washed once with RPMI medium, and resuspended in RPMI medium containing 20% fetal calf serum. The endothelial cells were plated on 25-cm2 culture flasks coated with 1% gelatin. The cultures were left undisturbed for 48 hours at 37°C in an atmosphere of 5% CO2 in air. The media were then changed every other day. Endothelial cells started growing from small clumps of cells and spread to confluence within 5-10 days. Monolayer cultures exhibited a typical cobblestone morphology of endothelial cells. Once confluence was obtained, the cells were detached with Puck-EDTA solution and trypsin and transferred to multiwell containers and culture flasks in order to proceed with additional experiments. The presence of endothelial cell markers was used to confirm purity of the cell cultures. Incorporation of 1,1'-dioctadecyl-1-2,3,3'-tetramethyl-indocarboxyanine perchlorate acetylated low density lipoprotein (dil-Ac-LDL) by the endothelial cells was determined by immunofluorescence.1" Rabbit pulmonary artery smooth muscle cells were cultured by treating vessels as described for pulmonary artery endothelial cells. After collection of endothelial cells, strips of denuded vessels were placed into gelatincoated flasks with medium 199 containing 10% fetal calf serum with L-glutamine (1%), tyrosine (0.1%), and antibiotics (0.15% nystatin and 0.15% gentamycin). Smooth muscle cells migrated to the flasks within 3-5 days. Once growth was established on the coated flasks, the vessels were removed, and the cells were fed as described for endothelial cells. Purity of smooth muscle cells was confirmed by positive staining for smooth muscle cell a-actin.
Immunohistochemical studies were performed on endothelial and smooth muscle cells in multiwell containers. 12 The cells were washed with phosphate-buffered saline (PBS) consisting of 20 mM NaCI, 2.7 mM KCl, 10 mM phosphate buffer, and 0. Figure 1B) . Little or no contractions to AA were observed with the TXA2/PGH2 receptor antagonist SQ29548 (maximal response, 3.1 + 1.1%; p<0.05; Figure 1B ). At Similar contractions were seen when cumulative concentrations of MeCH were added to rabbit intrapulmonary rings. The maximal response was 95.5 +4.6 % of the KCI contraction and occurred with 3 x 10-5 M (p<0.01, Figure 1A ). The ED50 for MeCH was 3.xlO -6 By use of a superfusion bioassay, AA promoted the contraction of an indomethacin-treated denuded detector vessel when added to the perfusate of an endothelium-intact donor vessel. In contrast, it had no effect when added directly to the detector vessel superfusate (Figure 2, top panel) . PGH2, U46619, and KCI, however, contracted the detector vessels when added directly. When perfused through the donor vessel, indomethacin inhibited the AA-induced contractions (data not shown). By comparing the constrictor responses in sequential detector vessels that were separated by a known time delay, the approximate half-life (tl12) could be determined (Figure 2, bottom panel) . The only a small radioactive peak that comigrated with 6-keto-PGFla was observed ( Figure 3D ). Pretreatment with SQ29528 had no effect on the metabolism of
[14C]AA (data not shown).
In a separate experiment, the radioactive peak that comigrated with TXB2 was collected, extracted with cyclohexane/ethyl acetate (50: 50), and rechromatographed using a normal-phase HPLC system (Figure 4) . The radioactive product eluting at 24 minutes in this system comigrated with the authentic TXB2 standard. Additionally, a radioactive peak was observed at 5 minutes. 
Radioimmunoassays
To quantitate the production of prostacyclin and TXA2 by the rabbit pulmonary artery, strips of vessel were incubated with increasing concentrations of AA and MeCH, and the amounts of 6-keto-PGFia and TXB2 released into the buffer were measured by RIA. Both AA and MeCH caused concentration-related increases in 6-keto-PGFi, and TXB2 production ( Figure   6 ). The basal release of 6-keto-PGF1, exceeded TXB2.
This relation was maintained after stimulation by AA and MeCH. At the maximal concentration used (10M ), AA elicited an approximate sixfold increase in 6-keto-PGFl, production and a 14-fold increase in TXB2 production as compared with control values (Figure 6, p<0.05) . Similarly, MeCH (10`M) increased 6-keto-PGFla and TXB2 by twofold and eightfold, respectively ( Figure 6, p<O0.05) .
Indomethacin pretreatment significantly decreased the production of both 6-keto-PGF,0 (percent inhibi- (Figure 9 ). When smooth muscle cells grown in culture were treated with anti-TX synthase or preimmune serum, no fluorescent response was observed ( Figure 9 ).
Isolated rabbit pulmonary artery endothelial cells grown in culture were incubated with ['4C]AA, the media were extracted, and the [L4C]metabolites were resolved by HPLC (Figure 10 ). The major radioactive peaks comigrated with 6-keto-PGFi, and PGE2. The radioactive peak that comigrated with PGE2 was larger than that seen in rabbit pulmonary artery tissue incubated in a similar fashion. This finding is consistent with our previous results with human pulmonary endothelial cells. 13 The lack of effect of dazoxiben as well as the inability of MeCH to release TXB2 led the authors to conclude that PGH2, not TXA2, was the EDCF.
In our study, the endothelium-dependent contractions elicited by both AA and MeCH were blocked by indomethacin, dazoxiben, or SQ29548. This would appear to indicate that TXA2 was the contracting factor of pulmonary arteries. Further evidence indicated that this factor was a labile transferable factor released by the endothelium with a tl,2 that was shorter than the tlh2 of PGH2 but comparable to the tl/2 of TXA2. To confirm the production of TXA2 by rabbit pulmonary artery, strips of pulmonary artery equivalent in size to the rings were incubated with AA and MeCH, and the production of 6-keto-PGFia and TXB2 was measured by RIA. Results showed concentration-dependent production of 6-keto-PGFl, and TXB2. TXB2 production was inhibited by dazoxiben and indomethacin in a manner similar to that seen in the vascular reactivity studies. Additional evidence that TXA2 was produced by rabbit pulmonary artery was provided by chromatographic analysis using two different HPLC systems. In both, a metabolite of AA comigrated with a known TXB2 standard. When pulmonary artery was incubated with dazoxiben, the metabolite that comigrated with TXB2 was inhibited.
Finally, analysis of this metabolite by GC/MS confirmed that the rabbit pulmonary artery produced TXB2.
Thus, the evidence from these experiments provide strong support that TXA2 is the EDCF released by AA and MeCH in rabbit pulmonary artery. In all the previous reports, the identity of EDCF was based solely on experiments with TX synthase inhibitors and TXA2/ PGH2 receptor antagonists.1-5 Using a variety of techniques, including vascular reactivity studies with inhibitors, bioassay, and HPLC, RIA, and GC/MS analysis, we conclusively show that TXA2 is EDCF in rabbit pulmonary artery. More important, it is the only study to provide chemical evidence for the identity of EDCF. It should be noted that there could be an intrinsic difference in the nature of EDCF between the various types of vascular beds. Thus, it is possible that the EDCF released by the aorta of the SHR is PGH2 and that released from the rabbit pulmonary artery is TXA2.
The question remains as to which cell type(s) in the pulmonary artery produces TXA2. Possible candidates include endothelial cells or some type of cell adhering to or associated with the vessel intima. Concerning the latter possibility, platelets or macrophages are likely candidates, since TXA2 is their major AA metabolite.
Conflicting evidence exists over the ability of endothelial cells to produce TXA2. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] In our studies, immunofluorescence of rabbit pulmonary endothelial cells failed to show the presence of TX synthase, whereas the presence of cyclooxygenase was clearly shown. In addition, endothelial cells grown in culture and incu- In summary, we conclude that the EDCF released from rabbit pulmonary artery in response to AA and MeCH is TXA2. Our data suggest that endothelial cells may not be the source of this vasoconstrictor factor, since neither TX synthase nor TXB2 production is detected in rabbit pulmonary endothelial cells grown in culture. Further experiments examining the presence of adherent or resident cell types in the intima of the pulmonary artery should reveal the cellular source of EDCF.
